(Q43273738)

18 November 2017

title

Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis (English)

1 reference

18 November 2017

main subject

esthesioneuroblastoma

1 reference

9

Jürgen Meixensberger

1 reference

18 November 2017

Ronald Koschny

1

1 reference

18 November 2017

Heidrun Holland

2

1 reference

18 November 2017

Jaromir Sykora

3

1 reference

18 November 2017

Hande Erdal

4

1 reference

18 November 2017

Wolfgang Krupp

5

1 reference

18 November 2017

Manfred Bauer

6

1 reference

18 November 2017

Ulrike Bockmuehl

7

1 reference

18 November 2017

Peter Ahnert

8

1 reference

18 November 2017

Wolfgang Stremmel

10

1 reference

18 November 2017

Henning Walczak

11

1 reference

18 November 2017

Tom M Ganten

12

1 reference

18 November 2017

publication date

20 September 2009

1 reference

Journal of Neuro-Oncology

18 November 2017

published in

1 reference

18 November 2017

volume

97

1 reference

18 November 2017

issue

2

1 reference

18 November 2017

page(s)

171-185

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-009-0010-6

18 November 2017

exact match

0 references

cites work

The promise of TRAIL--potential and risks of a novel anticancer therapy

1 reference

12 December 2020

Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells

1 reference

12 December 2020

Esthesioneuroblastoma: prognosis and management.

1 reference

12 December 2020

[Olfactory neuroblastoma with spinal metastasis: case report]

1 reference

12 December 2020

To kill a tumor cell: the potential of proapoptotic receptor agonists

1 reference

12 December 2020

Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival

1 reference

12 December 2020

Regulation of N-myc expression in development and disease

1 reference

12 December 2020

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

1 reference

12 December 2020

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

1 reference

12 December 2020

Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.

1 reference

12 December 2020

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

1 reference

12 December 2020

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

1 reference

12 December 2020

Cytogenetic and molecular evaluation of clinically aggressive esthesioneuroblastoma

1 reference

12 December 2020

Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center

1 reference

12 December 2020

Esthesioneuroblastoma: a meta-analysis and review

1 reference

12 December 2020

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

1 reference

12 December 2020

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Esthesioneuroblastoma: The Princess Margaret Hospital experience

1 reference

12 December 2020

Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.

1 reference

12 December 2020

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

1 reference

12 December 2020

TRAIL as a target in anti-cancer therapy

1 reference

12 December 2020

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

1 reference

12 December 2020

Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis

1 reference

12 December 2020

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

1 reference

12 December 2020

Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.

1 reference

12 December 2020

Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

1 reference

12 December 2020

Bortezomib as a therapeutic candidate for neuroblastoma.

1 reference

12 December 2020

TRAIL-induced signalling and apoptosis

1 reference

12 December 2020

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

12 December 2020

Comprehensive cytogenetic characterization of an esthesioneuroblastoma

1 reference

12 December 2020

Caspase 8 is absent or low in many ex vivo gliomas.

1 reference

12 December 2020

Diagnosis and management of esthesioneuroblastoma

1 reference

12 December 2020

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

12 December 2020

Management of intracranial invasive olfactory neuroblastoma.

1 reference

12 December 2020

TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges

1 reference

12 December 2020

10.1007/S11060-009-0010-6

Identifiers

DOI

1 reference

Dimensions Publication ID

18 November 2017

1015783510

0 references

1 reference